High-dose third-generation EGFR-TKIs combined with intrathecal pemetrexed in advanced EGFR-mutant NSCLC with leptomeningeal metastases following EGFR-TKI therapy
High-dose third-generation EGFR-TKIs combined with pemetrexed intrathecal chemotherapy demonstrated a high rate of intracranial symptom relief and manageable safety in patients with EGFRm NSCLC who developed leptomeningeal metastases after previous EGFR-TKI therapy.
Authors
- Wei Yu (ORCID: https://orcid.org/0000-0002-8913-5985)
- Zhengang Qiu
- Linfang Liu (ORCID: https://orcid.org/0000-0001-6090-8799)
- Wenjuan Zhong (ORCID: https://orcid.org/0000-0002-9804-8197)
- Shugui Wu
- Longqiu Wu
- Huaqiu Shi
Institutions
- First Affiliated Hospital of Jiangxi Medical College (CN)
- Ganzhou People's Hospital (CN)
- Jiangxi Provincial Cancer Hospital (CN)
- Gannan Medical University (CN)
- First Affiliated Hospital of Gannan Medical University (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-05-23
- DOI
- https://doi.org/10.1186/s12885-025-14337-z
- Citations
- 2
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 3.04